22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › CRISPR THERAPEUTICS AG › 2024-2025

CRISPR THERAPEUTICS AG 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and CRISPR THERAPEUTICS AG’s Form 8-K, filed June 9, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 43Reported items
  • 440Asset managers, any item
  • 4,250Fund votes
  • June 5, 2025Meeting date

Results at a glance

Meeting of June 5, 2025: 23 items on CRISPR THERAPEUTICS AG’s Form 8-K, filed June 9, 2025: 15 elected · 6 approved · 2 passed (calculated).

Dissent

Significant dissent: 2 directors (27.5%, 27.0% against).

  • Elect Director: Ali Behbahani, M.D. 73% of votes cast Elected Significant · 27.5% against
  • Elect Director: Ali Behbahani, M.D. 73% of votes cast Elected Significant · 27.0% against

Notable dissent: 1 say-on-pay vote (71.2% support); 1 other board item (47.7% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore CRISPR THERAPEUTICS AG in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by CRISPR THERAPEUTICS AG

These tallies are CRISPR THERAPEUTICS AG’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CRISPR THERAPEUTICS AG — official shareholder meeting results, meeting held June 5, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
1. Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the Year Ended December 31, 2024 61,111,040269,172378,214 --0 99.6%Approved—
2. Approval of the Appropriation of Financial Results 61,108,372309,602340,452 --0 99.5%Approved—
3. Discharge of the Members of the Company’s Board of Directors and Executive Committee 40,609,346211,187115,780 --20,822,113 99.5%Approved—
Elect Director: Samarth Kulkarni, Ph.D. 40,043,203785,309107,801 --20,822,113 98%Elected—
Elect Director: Ali Behbahani, M.D. 29,800,90211,023,256112,155 --20,822,113 73%Elected—
Elect Director: Maria Fardis, Ph.D. 39,931,396898,012106,905 --20,822,113 98%Elected—
Elect Director: H. Edward Fleming Jr., M.D. 39,553,9601,273,549108,804 --20,822,113 97%Elected—
Elect Director: Simeon J. George, M.D. 39,938,669894,244103,400 --20,822,113 98%Elected—
Elect Director: John T. Greene 39,324,9181,499,057112,338 --20,822,113 96%Elected—
Elect Director: Katherine A. High, M.D. 39,882,598946,656107,059 --20,822,113 98%Elected—
Elect Director: Sandesh Mahatme, LL.M. 39,915,991918,369101,953 --20,822,113 98%Elected—
Elect Director: Christian Rommel, Ph.D. 39,928,435899,491108,387 --20,822,113 98%Elected—
Elect Director: Douglas A. Treco, Ph.D. 38,935,8551,892,354108,104 --20,822,113 95%Elected—
Elect Director: Briggs W. Morrison, M.D. 39,667,0431,160,681108,589 --20,822,113 97%Elected—
Elect Director: Ali Behbahani, M.D. 29,606,11411,206,197124,002 --20,822,113 73%Elected—
Elect Director: H. Edward Fleming Jr., M.D. 39,457,8081,356,562121,943 --20,822,113 97%Elected—
Elect Director: John T. Greene 39,257,1501,550,619128,544 --20,822,113 96%Elected—
Elect Director: Briggs W. Morrison, M.D. 39,579,3461,234,698122,269 --20,822,113 97%Elected—
7. Non-Binding Advisory Vote on the Compensation Paid to the Company’s Named Executive Officers Under U.S. Securities Law Requirements 29,063,58611,729,542143,185 --20,822,113 71%Approved—
8. Approval of Increasing the Maximum Size of the Board of Directors 59,340,0171,990,224428,185 --0 97%Approved—
9. Re-election of the Independent Voting Rights Representative 60,711,637719,349327,440 --0 99%Passed (calculated)—
10. Re-election of the Auditors 60,674,825340,077743,524 --0 99.4%Passed (calculated)—
11. Transact Any Other Business that may Properly Come Before the 2025 Annual General Meeting or any Adjournment or Postponement thereof 21,319,10619,405,679211,528 --20,822,113 52.3%Approved—

Source: CRISPR THERAPEUTICS AG, Form 8-K, filed with the SEC on June 9, 2025 — read the filing on EDGAR.

How asset managers voted at the CRISPR THERAPEUTICS AG 2024-2025 meeting

440 asset managers disclosed a vote on at least one CRISPR THERAPEUTICS AG item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CRISPR THERAPEUTICS AG’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Discharge of the Members of the Company’s Board of Directors and Executive Committee

Official resultOTHERReported outcome: Approved

99.5% Approved · of votes cast

FOR 99.5%
FOR: 40,609,346AGAINST: 211,187
Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: Discharge of the members of the Board of Directors and the Executive Committee.

CRISPR THERAPEUTICS AG’s own tally for this item (“3. Discharge of the Members of the Company’s Board of Directors and Executive Committee”): 40,609,346 for, 211,187 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Discharge of the Members of the Company’s Board of Directors and Executive Committee The discharge of the members of the Company’s Board of Directors and the Executive Committee from personal liability for their activities during the year ended December 31, 2024 was approved.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 18,324,341 for, 0 against, 0 abstained.

FOR
FOR: 18,324,341AGAINST: 0ABSTAIN: 0
Largest asset managers voting on “Discharge of the members of the Board of Directors and the Executive Committee.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
Jackson National283,4720 00For
State Street233,9740 00For
Vanguard221,2230 00For
Fidelity151,6410 00For
Charles Schwab88,9480 00For
Natixis83,3720 00For
Equitable56,9460 00For
Lincoln Financial55,5450 00For
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST39,3670 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust28,7690 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
ADVISORS SERIES TRUST17,3100 00For
American Century16,4020 00For
Nationwide16,1110 00For
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Elect Director: Christian Rommel, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 39,928,435AGAINST: 899,491

Prior year: 99.6% for (May 30, 2024 meeting) ▼ 1.8 pts

Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: i Re-election of Christian Rommel, Ph.D.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Christian Rommel, Ph.D.”): 39,928,435 for, 899,491 against, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Election or Re-election of the Members to the Board of Directors and the Chairman Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Christian Rommel, P…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 17,924,922 for, 396,549 against, 2,840 abstained.

FOR
FOR: 17,924,922AGAINST: 396,549ABSTAIN: 2,840
Largest asset managers voting on “i Re-election of Christian Rommel, Ph.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
Jackson National105,532177,940 00Mixed
State Street233,9740 00For
Vanguard221,2230 00For
Fidelity151,6410 00For
Charles Schwab88,9480 00For
Natixis083,372 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST39,3670 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust28,7690 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
ADVISORS SERIES TRUST17,3100 00For
American Century16,4020 00For
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Elect Director: Douglas A. Treco, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 38,935,855AGAINST: 1,892,354

Prior year: 95.0% for (May 30, 2024 meeting) ▲ 0.3 pts

Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: j Re-election of Douglas A. Treco, Ph.D.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Douglas A. Treco, Ph.D.”): 38,935,855 for, 1,892,354 against, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Election or Re-election of the Members to the Board of Directors and the Chairman Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Christian Rommel, P…”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 17,647,540 for, 676,771 against, 0 abstained.

FOR
FOR: 17,647,540AGAINST: 676,771ABSTAIN: 0
Largest asset managers voting on “j Re-election of Douglas A. Treco, Ph.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
Jackson National105,532177,940 00Mixed
State Street0233,974 00Against
Vanguard221,2230 00For
Fidelity115,41536,226 00Mixed
Charles Schwab88,9480 00For
Natixis083,372 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST39,3670 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust28,7690 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
ADVISORS SERIES TRUST17,3100 00For
American Century16,4020 00For
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Elect Director: Katherine A. High, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 39,882,598AGAINST: 946,656

Prior year: 99.4% for (May 30, 2024 meeting) ▼ 1.7 pts

Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: g Re-election of Katherine A. High, M.D.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Katherine A. High, M.D.”): 39,882,598 for, 946,656 against, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Election or Re-election of the Members to the Board of Directors and the Chairman Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Christian Rommel, P…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 17,927,762 for, 396,549 against, 0 abstained.

FOR
FOR: 17,927,762AGAINST: 396,549ABSTAIN: 0
Largest asset managers voting on “g Re-election of Katherine A. High, M.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
Jackson National105,532177,940 00Mixed
State Street233,9740 00For
Vanguard221,2230 00For
Fidelity151,6410 00For
Charles Schwab88,9480 00For
Natixis083,372 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST39,3670 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust28,7690 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
ADVISORS SERIES TRUST17,3100 00For
American Century16,4020 00For
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Elect Director: Maria Fardis, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 39,931,396AGAINST: 898,012

Prior year: 98.4% for (May 30, 2024 meeting) ▼ 0.6 pts

Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: c Re-election of Maria Fardis, Ph.D.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Maria Fardis, Ph.D.”): 39,931,396 for, 898,012 against, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Election or Re-election of the Members to the Board of Directors and the Chairman Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Christian Rommel, P…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 17,927,762 for, 396,549 against, 0 abstained.

FOR
FOR: 17,927,762AGAINST: 396,549ABSTAIN: 0
Largest asset managers voting on “c Re-election of Maria Fardis, Ph.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
Jackson National105,532177,940 00Mixed
State Street233,9740 00For
Vanguard221,2230 00For
Fidelity151,6410 00For
Charles Schwab88,9480 00For
Natixis083,372 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST39,3670 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust28,7690 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
ADVISORS SERIES TRUST17,3100 00For
American Century16,4020 00For
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Elect Director: Samarth Kulkarni, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 40,043,203AGAINST: 785,309

Prior year: 98.8% for (May 30, 2024 meeting) ▼ 0.8 pts

Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: Election or re-election of the members to the Board of Directors and the Chairman: 4.a Re-election of Samarth Kulkarni, Ph.D., as member and Chairman

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Samarth Kulkarni, Ph.D.”): 40,043,203 for, 785,309 against, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Election or Re-election of the Members to the Board of Directors and the Chairman Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Christian Rommel, P…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 18,302,011 for, 22,300 against, 0 abstained.

FOR
FOR: 18,302,011AGAINST: 22,300ABSTAIN: 0
Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: 4.a Re-election of Samarth ” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
Jackson National283,4720 00For
State Street233,9740 00For
Vanguard221,2230 00For
Fidelity151,6410 00For
Charles Schwab88,9480 00For
Natixis83,3720 00For
Equitable56,9460 00For
Lincoln Financial55,5450 00For
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST39,3670 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust28,7690 00For
Capitol Series Trust022,300 00Against
Global X22,2930 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
ADVISORS SERIES TRUST17,3100 00For
American Century16,4020 00For
Nationwide16,1110 00For
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Elect Director: Sandesh Mahatme, LL.M.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 39,915,991AGAINST: 918,369

Prior year: 99.6% for (May 30, 2024 meeting) ▼ 1.8 pts

Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: h Re-election of Sandesh Mahatme, LL.M.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Sandesh Mahatme, LL.M.”): 39,915,991 for, 918,369 against, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Election or Re-election of the Members to the Board of Directors and the Chairman Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Christian Rommel, P…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 17,927,762 for, 396,549 against, 0 abstained.

FOR
FOR: 17,927,762AGAINST: 396,549ABSTAIN: 0
Largest asset managers voting on “h Re-election of Sandesh Mahatme, LL.M.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
Jackson National105,532177,940 00Mixed
State Street233,9740 00For
Vanguard221,2230 00For
Fidelity151,6410 00For
Charles Schwab88,9480 00For
Natixis083,372 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST39,3670 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust28,7690 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
ADVISORS SERIES TRUST17,3100 00For
American Century16,4020 00For
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Elect Director: Simeon J. George, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 39,938,669AGAINST: 894,244
Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: e Re-election of Simeon J. George, M.D.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Simeon J. George, M.D.”): 39,938,669 for, 894,244 against, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Election or Re-election of the Members to the Board of Directors and the Chairman Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Christian Rommel, P…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 17,927,762 for, 396,549 against, 0 abstained.

FOR
FOR: 17,927,762AGAINST: 396,549ABSTAIN: 0
Largest asset managers voting on “e Re-election of Simeon J. George, M.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
Jackson National105,532177,940 00Mixed
State Street233,9740 00For
Vanguard221,2230 00For
Fidelity151,6410 00For
Charles Schwab88,9480 00For
Natixis083,372 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST39,3670 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust28,7690 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
ADVISORS SERIES TRUST17,3100 00For
American Century16,4020 00For
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Re-election of the Independent Voting Rights Representative

Calculated outcomeCORPORATE GOVERNANCEPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 60,711,637AGAINST: 719,349
Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: Re-election of the independent voting rights representative.

CRISPR THERAPEUTICS AG’s own tally for this item (“9. Re-election of the Independent Voting Rights Representative”): 60,711,637 for, 719,349 against, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 18,324,311 for, 0 against, 0 abstained.

FOR
FOR: 18,324,311AGAINST: 0ABSTAIN: 0
Largest asset managers voting on “Re-election of the independent voting rights representative.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
Jackson National283,4720 00For
State Street233,9740 00For
Vanguard221,2230 00For
Fidelity151,6410 00For
Charles Schwab88,9480 00For
Natixis83,3720 00For
Equitable56,9460 00For
Lincoln Financial55,5450 00For
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST39,3670 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust28,7690 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
ADVISORS SERIES TRUST17,3100 00For
American Century16,4020 00For
Nationwide16,1110 00For
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2025…

Combines 4 wordings of this item as funds reported it.

99.9% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 37 asset managers

Description as filed by funds: Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 21 asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Jackson National283,4720 00For
Charles Schwab88,9480 00For
Natixis83,3720 00For
AMERICAN BEACON FUNDS53,3570 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
ADVISORS SERIES TRUST17,3100 00For
BlackRock10,0220 00For
Loomis Sayles6,6350 00For
EA Series Trust2,8400 00For
Allianz2,1340 00For
JPMorgan1,3940 00For
CITY NATIONAL ROCHDALE FUNDS4100 00For
Amplify ETF Trust2240 00For
Jacob Funds Inc.1500 00For
John Hancock1260 00For
Listed Funds Trust980 00For
Vanguard110 00For

Fund voting reports, all 21 managers: 10,184,111 for, 0 against, 0 abstained.

Institutional-manager reports: 16 asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
NEA Management Company, LLC1,590,0020 00For
SR ONE CAPITAL MANAGEMENT, LP1,048,9510 00For
Versant Venture Management, LLC500,0280 00For
Janney Montgomery Scott LLC10,8190 00For
BRANDYWINE OAK PRIVATE WEALTH LLC2,5000 00For
L. Roy Papp & Associates, LLP1,0000 00For
EXENCIAL WEALTH ADVISORS, LLC3180 00For
Rodgers Brothers Inc.0300 00Against
Alexander Randolph Advisory, Inc.2100 00For
Sterling Investment Counsel, LLC2000 00For
Summit Trail Advisors, LLC1930 00For
NORTHCAPE WEALTH MANAGEMENT, LLC1640 00For
BIRCHBROOK, INC.1000 00For
Petros Family Wealth, LLC850 00For
Hendershot Investments Inc.010 00Against
BRADY FAMILY WEALTH, LLC10 00For

Institutional-manager reports, all 16 managers: 3,154,571 for, 310 against.

Binding vote on maximum equity for members of the Board of Directors from the 2025 Annual General Meeting to the 2026…

Combines 4 wordings of this item as funds reported it.

96% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 30 asset managers

Description as filed by funds: Binding vote on maximum equity for members of the Board of Directors from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 21 asset managers voting on “Binding vote on maximum equity for members of the Board of Directors from the 2025 Annual General Meeting to t” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Jackson National86,878196,594 00Mixed
Charles Schwab088,948 00Against
Natixis083,372 00Against
AMERICAN BEACON FUNDS53,3570 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Capitol Series Trust022,300 00Against
Global X022,293 00Against
ADVISORS SERIES TRUST17,3100 00For
BlackRock10,0220 00For
Loomis Sayles06,635 00Against
EA Series Trust2,8400 00For
Allianz02,134 00Against
JPMorgan1,3940 00For
CITY NATIONAL ROCHDALE FUNDS0410 00Against
Amplify ETF Trust2240 00For
Jacob Funds Inc.1500 00For
John Hancock1260 00For
Listed Funds Trust980 00For
Vanguard010 00Against

Fund voting reports, all 21 managers: 9,761,414 for, 422,696 against, 0 abstained.

Institutional-manager reports: 9 asset managers voting on “Binding vote on maximum equity for members of the Board of Directors from the 2025 Annual General Meeting to t” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
SR ONE CAPITAL MANAGEMENT, LP1,048,9510 00For
Versant Venture Management, LLC500,0280 00For
BRANDYWINE OAK PRIVATE WEALTH LLC2,5000 00For
L. Roy Papp & Associates, LLP1,0000 00For
Rodgers Brothers Inc.0300 00Against
NORTHCAPE WEALTH MANAGEMENT, LLC1640 00For
BIRCHBROOK, INC.1000 00For
Hendershot Investments Inc.010 00Against
BRADY FAMILY WEALTH, LLC10 00For

Institutional-manager reports, all 9 managers: 1,552,744 for, 310 against.

B Re-election of Ali Behbahani, M.D.

No official matchDIRECTOR ELECTIONS

70% of fund votes cast · no official result

FORAGAINST
Details: description as filed, votes by 29 asset managers

Description as filed by funds: b Re-election of Ali Behbahani, M.D.

The 29 asset managers below reported 5,727,410 for, 2,409,220 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 5,727,410AGAINST: 2,409,220
Largest asset managers voting on “b Re-election of Ali Behbahani, M.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group5,493,2290 00For
T. Rowe Price01,735,454 00Against
State Street233,9740 00For
Vanguard0221,212 00Against
Fidelity0151,641 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
RMB INVESTORS TRUST039,367 00Against
Direxion Shares ETF Trust028,769 00Against
Northern Trust022,183 00Against
MassMutual019,636 00Against
American Century016,402 00Against
Nationwide016,111 00Against
Northwestern Mutual014,200 00Against
Blackstone Alternative Investment Funds012,700 00Against
Guggenheim07,735 00Against
ProShares04,884 00Against
Empower02,243 00Against
Dimensional01,024 00Against
Franklin Templeton0737 00Against
SA FUNDS INVESTMENT TRUST0708 00Against
Prudential/PGIM0618 00Against
WisdomTree0573 00Against
Goldman Sachs0263 00Against
Invesco2070 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

D Re-election of H. Edward Fleming, Jr., M.D.

No official matchDIRECTOR ELECTIONS

97% of fund votes cast · no official result

FOR
Details: description as filed, votes by 29 asset managers

Description as filed by funds: d Re-election of H. Edward Fleming, Jr., M.D.

The 29 asset managers below reported 7,889,690 for, 246,940 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,889,690AGAINST: 246,940
Largest asset managers voting on “d Re-election of H. Edward Fleming, Jr., M.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
State Street233,9740 00For
Vanguard221,2120 00For
Fidelity36,226115,415 00Mixed
Equitable056,946 00Against
Lincoln Financial055,545 00Against
RMB INVESTORS TRUST39,3670 00For
Direxion Shares ETF Trust28,7690 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
American Century16,4020 00For
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For
Guggenheim7,7350 00For
ProShares4,8840 00For
Empower2,2430 00For
Dimensional01,024 00Against
Franklin Templeton7370 00For
SA FUNDS INVESTMENT TRUST0708 00Against
Prudential/PGIM0618 00Against
WisdomTree0573 00Against
Goldman Sachs2630 00For
Invesco2070 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

F Re-election of John T. Greene

No official matchDIRECTOR ELECTIONS

97% of fund votes cast · no official result

FOR
Details: description as filed, votes by 29 asset managers

Description as filed by funds: f Re-election of John T. Greene

The 29 asset managers below reported 7,853,464 for, 283,166 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,853,464AGAINST: 283,166
Largest asset managers voting on “f Re-election of John T. Greene” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
State Street233,9740 00For
Vanguard221,2120 00For
Fidelity0151,641 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
RMB INVESTORS TRUST39,3670 00For
Direxion Shares ETF Trust28,7690 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
American Century16,4020 00For
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For
Guggenheim7,7350 00For
ProShares4,8840 00For
Empower2,2430 00For
Dimensional01,024 00Against
Franklin Templeton7370 00For
SA FUNDS INVESTMENT TRUST0708 00Against
Prudential/PGIM0618 00Against
WisdomTree0573 00Against
Goldman Sachs2630 00For
Invesco2070 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

K Election of Briggs W. Morrison, M.D.

No official matchDIRECTOR ELECTIONS

97% of fund votes cast · no official result

FOR
Details: description as filed, votes by 29 asset managers

Description as filed by funds: k Election of Briggs W. Morrison, M.D.

The 29 asset managers below reported 7,892,613 for, 244,017 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,892,613AGAINST: 244,017
Largest asset managers voting on “k Election of Briggs W. Morrison, M.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
State Street233,9740 00For
Vanguard221,2120 00For
Fidelity36,226115,415 00Mixed
Equitable056,946 00Against
Lincoln Financial055,545 00Against
RMB INVESTORS TRUST39,3670 00For
Direxion Shares ETF Trust28,7690 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
American Century16,4020 00For
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For
Guggenheim7,7350 00For
ProShares4,8840 00For
Empower2,2430 00For
Dimensional1,0240 00For
Franklin Templeton7370 00For
SA FUNDS INVESTMENT TRUST7080 00For
Prudential/PGIM6180 00For
WisdomTree5730 00For
Goldman Sachs2630 00For
Invesco2070 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

B Re-election of H. Edward Fleming, Jr., M.D.

No official matchDIRECTOR ELECTIONSCORPORATE GOVERNANCE

97% of fund votes cast · no official result

FOR
Details: description as filed, votes by 29 asset managers

Description as filed by funds: b Re-election of H. Edward Fleming, Jr., M.D.

The 29 asset managers below reported 7,889,690 for, 246,940 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,889,690AGAINST: 246,940
Largest asset managers voting on “b Re-election of H. Edward Fleming, Jr., M.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
State Street233,9740 00For
Vanguard221,2120 00For
Fidelity36,226115,415 00Mixed
Equitable056,946 00Against
Lincoln Financial055,545 00Against
RMB INVESTORS TRUST39,3670 00For
Direxion Shares ETF Trust28,7690 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
American Century16,4020 00For
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For
Guggenheim7,7350 00For
ProShares4,8840 00For
Empower2,2430 00For
Dimensional01,024 00Against
Franklin Templeton7370 00For
SA FUNDS INVESTMENT TRUST0708 00Against
Prudential/PGIM0618 00Against
WisdomTree0573 00Against
Goldman Sachs2630 00For
Invesco2070 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

C Re-election of John T. Greene

No official matchDIRECTOR ELECTIONSCORPORATE GOVERNANCE

97% of fund votes cast · no official result

FOR
Details: description as filed, votes by 29 asset managers

Description as filed by funds: c Re-election of John T. Greene

The 29 asset managers below reported 7,853,464 for, 283,166 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,853,464AGAINST: 283,166
Largest asset managers voting on “c Re-election of John T. Greene” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
State Street233,9740 00For
Vanguard221,2120 00For
Fidelity0151,641 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
RMB INVESTORS TRUST39,3670 00For
Direxion Shares ETF Trust28,7690 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
American Century16,4020 00For
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For
Guggenheim7,7350 00For
ProShares4,8840 00For
Empower2,2430 00For
Dimensional01,024 00Against
Franklin Templeton7370 00For
SA FUNDS INVESTMENT TRUST0708 00Against
Prudential/PGIM0618 00Against
WisdomTree0573 00Against
Goldman Sachs2630 00For
Invesco2070 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

D Election of Briggs W. Morrison, M.D.

No official matchDIRECTOR ELECTIONSCORPORATE GOVERNANCE

97% of fund votes cast · no official result

FOR
Details: description as filed, votes by 29 asset managers

Description as filed by funds: d Election of Briggs W. Morrison, M.D.

The 29 asset managers below reported 7,892,613 for, 244,017 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,892,613AGAINST: 244,017
Largest asset managers voting on “d Election of Briggs W. Morrison, M.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
State Street233,9740 00For
Vanguard221,2120 00For
Fidelity36,226115,415 00Mixed
Equitable056,946 00Against
Lincoln Financial055,545 00Against
RMB INVESTORS TRUST39,3670 00For
Direxion Shares ETF Trust28,7690 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
American Century16,4020 00For
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For
Guggenheim7,7350 00For
ProShares4,8840 00For
Empower2,2430 00For
Dimensional1,0240 00For
Franklin Templeton7370 00For
SA FUNDS INVESTMENT TRUST7080 00For
Prudential/PGIM6180 00For
WisdomTree5730 00For
Goldman Sachs2630 00For
Invesco2070 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

B Binding vote on maximum equity for members of the Board of Directors from the 2025 Annual General Meeting to the 2026…

No official matchCOMPENSATION

94% of fund votes cast · no official result

FOR
Details: description as filed, votes by 29 asset managers

Description as filed by funds: b Binding vote on maximum equity for members of the Board of Directors from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders.

The 29 asset managers below reported 7,635,060 for, 501,570 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,635,060AGAINST: 501,570
Largest asset managers voting on “b Binding vote on maximum equity for members of the Board of Directors from the 2025 Annual General Meeting to” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group5,493,2290 00For
T. Rowe Price1,732,5302,924 00For
State Street0233,974 00Against
Vanguard221,2120 00For
Fidelity151,6410 00For
Equitable056,946 00Against
Lincoln Financial055,545 00Against
RMB INVESTORS TRUST039,367 00Against
Direxion Shares ETF Trust028,769 00Against
Northern Trust022,183 00Against
MassMutual19,6360 00For
American Century016,402 00Against
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds012,700 00Against
Guggenheim07,735 00Against
ProShares04,884 00Against
Empower2,2430 00For
Dimensional01,024 00Against
Franklin Templeton0737 00Against
SA FUNDS INVESTMENT TRUST0708 00Against
Prudential/PGIM0618 00Against
WisdomTree0573 00Against
Goldman Sachs0263 00Against
Invesco2070 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

Election or Re-election of the members of the Compensation Committee: 5.a Re-election of Ali Behbahani, M.D.

No official matchDIRECTOR ELECTIONSCORPORATE GOVERNANCE

70% of fund votes cast · no official result

FORAGAINST
Details: votes by 29 asset managers

The 29 asset managers below reported 5,727,203 for, 2,409,427 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 5,727,203AGAINST: 2,409,427
Largest asset managers voting on “Election or Re-election of the members of the Compensation Committee: 5.a Re-election of Ali Behbahani, M.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group5,493,2290 00For
T. Rowe Price01,735,454 00Against
State Street233,9740 00For
Vanguard0221,212 00Against
Fidelity0151,641 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
RMB INVESTORS TRUST039,367 00Against
Direxion Shares ETF Trust028,769 00Against
Northern Trust022,183 00Against
MassMutual019,636 00Against
American Century016,402 00Against
Nationwide016,111 00Against
Northwestern Mutual014,200 00Against
Blackstone Alternative Investment Funds012,700 00Against
Guggenheim07,735 00Against
ProShares04,884 00Against
Empower02,243 00Against
Dimensional01,024 00Against
Franklin Templeton0737 00Against
SA FUNDS INVESTMENT TRUST0708 00Against
Prudential/PGIM0618 00Against
WisdomTree0573 00Against
Goldman Sachs0263 00Against
Invesco0207 00Against

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

Election of the member of the Compensation Committee: Briggs W. Morrison, M.D.

No official matchDIRECTOR ELECTIONS

97% of fund votes cast · no official result

FOR
Details: votes by 27 asset managers

The 27 asset managers below reported 9,920,475 for, 267,947 against, 0 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 9,920,475AGAINST: 267,947ABSTAIN: 0
Largest asset managers voting on “Election of the member of the Compensation Committee: Briggs W. Morrison, M.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Jackson National105,532177,940 00Mixed
Charles Schwab88,9480 00For
Natixis083,372 00Against
AMERICAN BEACON FUNDS53,3570 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
ADVISORS SERIES TRUST17,3100 00For
BlackRock10,0220 00For
Loomis Sayles06,635 00Against
EA Series Trust2,8400 00For
BRANDYWINE OAK PRIVATE WEALTH LLC2,5000 00For
Allianz2,1340 00For
JPMorgan1,3940 00For
L. Roy Papp & Associates, LLP1,0000 00For
CITY NATIONAL ROCHDALE FUNDS4100 00For
EXENCIAL WEALTH ADVISORS, LLC3180 00For
Amplify ETF Trust2240 00For
Sterling Investment Counsel, LLC2000 00For
Summit Trail Advisors, LLC1930 00For
Jacob Funds Inc.1500 00For
John Hancock1260 00For
BIRCHBROOK, INC.1000 00For

Showing the 25 largest of 27 asset managers. All 27 are in the interactive database (link above).

Re-election of the member of the Compensation Committee: H. Edward Fleming, Jr., M.D.

No official matchDIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

96% of fund votes cast · no official result

FOR
Details: votes by 27 asset managers

The 27 asset managers below reported 9,810,315 for, 378,107 against, 0 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 9,810,315AGAINST: 378,107ABSTAIN: 0
Largest asset managers voting on “Re-election of the member of the Compensation Committee: H. Edward Fleming, Jr., M.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Jackson National86,878196,594 00Mixed
Charles Schwab088,948 00Against
Natixis083,372 00Against
AMERICAN BEACON FUNDS53,3570 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
ADVISORS SERIES TRUST17,3100 00For
BlackRock10,0220 00For
Loomis Sayles06,635 00Against
EA Series Trust2,8400 00For
BRANDYWINE OAK PRIVATE WEALTH LLC2,5000 00For
Allianz02,134 00Against
JPMorgan1,3940 00For
L. Roy Papp & Associates, LLP1,0000 00For
CITY NATIONAL ROCHDALE FUNDS4100 00For
EXENCIAL WEALTH ADVISORS, LLC3180 00For
Amplify ETF Trust0224 00Against
Sterling Investment Counsel, LLC0200 00Against
Summit Trail Advisors, LLC1930 00For
Jacob Funds Inc.1500 00For
John Hancock1260 00For
BIRCHBROOK, INC.1000 00For

Showing the 25 largest of 27 asset managers. All 27 are in the interactive database (link above).

Re-election of the member of the Compensation Committee: John T. Greene

No official matchDIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

96% of fund votes cast · no official result

FOR
Details: votes by 27 asset managers

The 27 asset managers below reported 9,800,293 for, 388,129 against, 0 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 9,800,293AGAINST: 388,129ABSTAIN: 0
Largest asset managers voting on “Re-election of the member of the Compensation Committee: John T. Greene” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Jackson National86,878196,594 00Mixed
Charles Schwab088,948 00Against
Natixis083,372 00Against
AMERICAN BEACON FUNDS53,3570 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
ADVISORS SERIES TRUST17,3100 00For
BlackRock010,022 00Against
Loomis Sayles06,635 00Against
EA Series Trust2,8400 00For
BRANDYWINE OAK PRIVATE WEALTH LLC2,5000 00For
Allianz02,134 00Against
JPMorgan1,3940 00For
L. Roy Papp & Associates, LLP1,0000 00For
CITY NATIONAL ROCHDALE FUNDS4100 00For
EXENCIAL WEALTH ADVISORS, LLC3180 00For
Amplify ETF Trust0224 00Against
Sterling Investment Counsel, LLC0200 00Against
Summit Trail Advisors, LLC1930 00For
Jacob Funds Inc.1500 00For
John Hancock1260 00For
BIRCHBROOK, INC.1000 00For

Showing the 25 largest of 27 asset managers. All 27 are in the interactive database (link above).

Election of Briggs W. Morrison, M.D.

No official matchDIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

97% of fund votes cast · no official result

FOR
Details: votes by 26 asset managers

The 26 asset managers below reported 9,962,554 for, 267,947 against, 0 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 9,962,554AGAINST: 267,947ABSTAIN: 0
Largest asset managers voting on “Election of Briggs W. Morrison, M.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Jackson National105,532177,940 00Mixed
Charles Schwab88,9480 00For
Natixis083,372 00Against
AMERICAN BEACON FUNDS53,3570 00For
Green Alpha Advisors, LLC40,3200 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
ADVISORS SERIES TRUST17,3100 00For
BlackRock10,0220 00For
Loomis Sayles06,635 00Against
EA Series Trust2,8400 00For
BRANDYWINE OAK PRIVATE WEALTH LLC2,5000 00For
WILLIAMSBURG INVESTMENT TRUST2,5000 00For
Allianz2,1340 00For
JPMorgan1,3940 00For
L. Roy Papp & Associates, LLP1,0000 00For
CITY NATIONAL ROCHDALE FUNDS4100 00For
Amplify ETF Trust2240 00For
Jacob Funds Inc.1500 00For
John Hancock1260 00For
Listed Funds Trust980 00For
MARCO INVESTMENT MANAGEMENT LLC700 00For

Showing the 25 largest of 26 asset managers. All 26 are in the interactive database (link above).

Re-election of the member of the Compensation Committee: Ali Behbahani, M.D.

No official matchDIRECTOR ELECTIONS

95% of fund votes cast · no official result

FOR
Details: votes by 26 asset managers

The 26 asset managers below reported 9,666,688 for, 521,540 against, 0 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 9,666,688AGAINST: 521,540ABSTAIN: 0
Largest asset managers voting on “Re-election of the member of the Compensation Committee: Ali Behbahani, M.D.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Jackson National0283,472 00Against
Charles Schwab088,948 00Against
Natixis083,372 00Against
AMERICAN BEACON FUNDS53,3570 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Capitol Series Trust022,300 00Against
Global X022,293 00Against
ADVISORS SERIES TRUST17,3100 00For
BlackRock010,022 00Against
Loomis Sayles06,635 00Against
EA Series Trust2,8400 00For
BRANDYWINE OAK PRIVATE WEALTH LLC2,5000 00For
Allianz02,134 00Against
JPMorgan01,394 00Against
L. Roy Papp & Associates, LLP1,0000 00For
CITY NATIONAL ROCHDALE FUNDS0410 00Against
EXENCIAL WEALTH ADVISORS, LLC3180 00For
Amplify ETF Trust0224 00Against
Sterling Investment Counsel, LLC0200 00Against
Jacob Funds Inc.1500 00For
John Hancock0126 00Against
BIRCHBROOK, INC.1000 00For
Listed Funds Trust980 00For

Showing the 25 largest of 26 asset managers. All 26 are in the interactive database (link above).

Approval of Increasing the Maximum Size of the Board of Directors

Official resultOTHERReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 59,340,017AGAINST: 1,990,224
Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: Approval of increasing the maximum size of the Board of Directors.

CRISPR THERAPEUTICS AG’s own tally for this item (“8. Approval of Increasing the Maximum Size of the Board of Directors”): 59,340,017 for, 1,990,224 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 8 – Approval of Increasing the Maximum Size of the Board of Directors An increase in the maximum size of the Board of Directors was approved with at least two thirds of the votes represented and the absolute majority of the par value of the represented shares.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 18,324,411 for, 0 against, 0 abstained.

FOR
FOR: 18,324,411AGAINST: 0ABSTAIN: 0
Largest asset managers voting on “Approval of increasing the maximum size of the Board of Directors.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
Jackson National283,4720 00For
State Street233,9740 00For
Vanguard221,2230 00For
Fidelity151,6410 00For
Charles Schwab88,9480 00For
Natixis83,3720 00For
Equitable56,9460 00For
Lincoln Financial55,5450 00For
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST39,3670 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust28,7690 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
ADVISORS SERIES TRUST17,3100 00For
American Century16,4020 00For
Nationwide16,1110 00For
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For

Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).

Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements…

Official resultOTHERReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

99.6% Approved · of votes cast

FOR 99.6%
FOR: 61,111,040AGAINST: 269,172
Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Approval of the Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2024.

CRISPR THERAPEUTICS AG’s own tally for this item (“1. Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the Year Ended December 31, 2024”): 61,111,040 for, 269,172 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 1 – Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the Year Ended December 31, 2024 The Swiss management report, the consolidated financial statements and the statutory financial statements of the Com…”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 18,326,811 for, 550 against, 0 abstained.

FOR
FOR: 18,326,811AGAINST: 550ABSTAIN: 0
Largest asset managers voting on “Approval of the Swiss management report, the consolidated financial statements and the statutory financial sta” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
Jackson National283,4720 00For
State Street233,9740 00For
Vanguard221,2230 00For
Fidelity151,6410 00For
Charles Schwab88,9480 00For
Natixis83,3720 00For
Equitable56,9460 00For
Lincoln Financial55,5450 00For
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST39,3670 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust28,7690 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
ADVISORS SERIES TRUST17,3100 00For
American Century16,4020 00For
Nationwide16,1110 00For
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Approval of the Appropriation of Financial Results

Official resultOTHERReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.5% Approved · of votes cast

FOR 99.5%
FOR: 61,108,372AGAINST: 309,602
Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: Approval of the appropriation of financial results.

CRISPR THERAPEUTICS AG’s own tally for this item (“2. Approval of the Appropriation of Financial Results”): 61,108,372 for, 309,602 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Approval of the Appropriation of Financial Results The proposal to carry forward the net income resulting from the appropriation of financial results was approved.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 18,324,311 for, 0 against, 0 abstained.

FOR
FOR: 18,324,311AGAINST: 0ABSTAIN: 0
Largest asset managers voting on “Approval of the appropriation of financial results.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
Jackson National283,4720 00For
State Street233,9740 00For
Vanguard221,2230 00For
Fidelity151,6410 00For
Charles Schwab88,9480 00For
Natixis83,3720 00For
Equitable56,9460 00For
Lincoln Financial55,5450 00For
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST39,3670 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust28,7690 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
ADVISORS SERIES TRUST17,3100 00For
American Century16,4020 00For
Nationwide16,1110 00For
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Transact Any Other Business that may Properly Come Before the 2025 Annual General Meeting or any Adjournment or…

Official resultCORPORATE GOVERNANCEReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

52.3% Approved · of votes cast

FOR 52.3%AGAINST
FOR: 21,319,106AGAINST: 19,405,679
Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: Transact any other business that may properly come before the 2025 Annual General Meeting or any adjournment or postponement thereof.

CRISPR THERAPEUTICS AG’s own tally for this item (“11. Transact Any Other Business that may Properly Come Before the 2025 Annual General Meeting or any Adjournment or Postponement thereof”): 21,319,106 for, 19,405,679 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 11 – Transact Any Other Business that may Properly Come Before the 2025 Annual General Meeting or any Adjournment or Postponement thereof The proposal for the transaction of any other business that properly came before the Annual Meeting or any adjournment or postponement thereof, to follo…”
Support: 52.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 9,662,324 for, 8,659,147 against, 2,840 abstained.

FORAGAINST
FOR: 9,662,324AGAINST: 8,659,147ABSTAIN: 2,840
Largest asset managers voting on “Transact any other business that may properly come before the 2025 Annual General Meeting or any adjournment o” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group05,493,229 00Against
T. Rowe Price01,735,454 00Against
Jackson National0283,472 00Against
State Street0233,974 00Against
Vanguard0221,223 00Against
Fidelity0151,641 00Against
Charles Schwab088,948 00Against
Natixis083,372 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST039,367 00Against
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust028,769 00Against
Capitol Series Trust022,300 00Against
Global X022,293 00Against
Northern Trust022,183 00Against
MassMutual019,636 00Against
ADVISORS SERIES TRUST17,3100 00For
American Century016,402 00Against
Nationwide016,111 00Against
Northwestern Mutual014,200 00Against
Blackstone Alternative Investment Funds012,700 00Against

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending…

Combines 5 wordings of this item as funds reported it.

98% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 36 asset managers

Description as filed by funds: Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2025.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 21 asset managers voting on “Binding vote on maximum variable compensation for members of the Executive Committee for the current year endi” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Jackson National86,878196,594 00Mixed
Charles Schwab88,9480 00For
Natixis083,372 00Against
AMERICAN BEACON FUNDS53,3570 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
ADVISORS SERIES TRUST17,3100 00For
BlackRock010,022 00Against
Loomis Sayles06,635 00Against
EA Series Trust2,8400 00For
Allianz02,134 00Against
JPMorgan1,3940 00For
CITY NATIONAL ROCHDALE FUNDS4100 00For
Amplify ETF Trust0224 00Against
Jacob Funds Inc.1500 00For
John Hancock1260 00For
Listed Funds Trust980 00For
Vanguard110 00For

Fund voting reports, all 21 managers: 9,885,130 for, 298,981 against, 0 abstained.

Institutional-manager reports: 15 asset managers voting on “Binding vote on maximum variable compensation for members of the Executive Committee for the current year endi” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
NEA Management Company, LLC1,590,0020 00For
SR ONE CAPITAL MANAGEMENT, LP1,048,9510 00For
Versant Venture Management, LLC500,0280 00For
Janney Montgomery Scott LLC10,8190 00For
BRANDYWINE OAK PRIVATE WEALTH LLC2,5000 00For
L. Roy Papp & Associates, LLP1,0000 00For
EXENCIAL WEALTH ADVISORS, LLC3180 00For
Rodgers Brothers Inc.0300 00Against
Sterling Investment Counsel, LLC0200 00Against
Summit Trail Advisors, LLC1930 00For
NORTHCAPE WEALTH MANAGEMENT, LLC1640 00For
BIRCHBROOK, INC.1000 00For
Petros Family Wealth, LLC850 00For
Hendershot Investments Inc.010 00Against
BRADY FAMILY WEALTH, LLC10 00For

Institutional-manager reports, all 15 managers: 3,154,161 for, 510 against.

Binding vote on maximum equity for members of the Executive Committee from the 2025 Annual General Meeting to the 2026…

Combines 4 wordings of this item as funds reported it.

96% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 31 asset managers

Description as filed by funds: Binding vote on maximum equity for members of the Executive Committee from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 21 asset managers voting on “Binding vote on maximum equity for members of the Executive Committee from the 2025 Annual General Meeting to ” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Jackson National86,878196,594 00Mixed
Charles Schwab088,948 00Against
Natixis083,372 00Against
AMERICAN BEACON FUNDS53,3570 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Capitol Series Trust022,300 00Against
Global X022,293 00Against
ADVISORS SERIES TRUST17,3100 00For
BlackRock010,022 00Against
Loomis Sayles06,635 00Against
EA Series Trust2,8400 00For
Allianz02,134 00Against
JPMorgan01,394 00Against
CITY NATIONAL ROCHDALE FUNDS0410 00Against
Amplify ETF Trust0224 00Against
Jacob Funds Inc.1500 00For
John Hancock1260 00For
Listed Funds Trust980 00For
Vanguard010 00Against

Fund voting reports, all 21 managers: 9,749,774 for, 434,336 against, 0 abstained.

Institutional-manager reports: 10 asset managers voting on “Binding vote on maximum equity for members of the Executive Committee from the 2025 Annual General Meeting to ” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
SR ONE CAPITAL MANAGEMENT, LP1,048,9510 00For
Versant Venture Management, LLC500,0280 00For
Dynasty Wealth Management, LLC25,1600 00For
BRANDYWINE OAK PRIVATE WEALTH LLC2,5000 00For
L. Roy Papp & Associates, LLP1,0000 00For
Rodgers Brothers Inc.0300 00Against
NORTHCAPE WEALTH MANAGEMENT, LLC1640 00For
BIRCHBROOK, INC.1000 00For
Hendershot Investments Inc.010 00Against
BRADY FAMILY WEALTH, LLC10 00For

Institutional-manager reports, all 10 managers: 1,577,904 for, 310 against.

D Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending…

No official matchCOMPENSATION

92% of fund votes cast · no official result

FOR
Details: description as filed, votes by 29 asset managers

Description as filed by funds: d Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2025.

The 29 asset managers below reported 7,483,212 for, 653,418 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,483,212AGAINST: 653,418
Largest asset managers voting on “d Binding vote on maximum variable compensation for members of the Executive Committee for the current year en” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group5,493,2290 00For
T. Rowe Price1,732,5302,924 00For
State Street0233,974 00Against
Vanguard221,2120 00For
Fidelity0151,641 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
RMB INVESTORS TRUST039,367 00Against
Direxion Shares ETF Trust028,769 00Against
Northern Trust022,183 00Against
MassMutual19,6360 00For
American Century016,402 00Against
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds012,700 00Against
Guggenheim07,735 00Against
ProShares04,884 00Against
Empower2,2430 00For
Dimensional01,024 00Against
Franklin Templeton0737 00Against
SA FUNDS INVESTMENT TRUST0708 00Against
Prudential/PGIM0618 00Against
WisdomTree0573 00Against
Goldman Sachs0263 00Against
Invesco0207 00Against

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

E Binding vote on maximum equity for members of the Executive Committee from the 2025 Annual General Meeting to the…

No official matchCOMPENSATION

89% of fund votes cast · no official result

FOR
Details: description as filed, votes by 29 asset managers

Description as filed by funds: e Binding vote on maximum equity for members of the Executive Committee from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders.

The 29 asset managers below reported 7,262,000 for, 874,630 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,262,000AGAINST: 874,630
Largest asset managers voting on “e Binding vote on maximum equity for members of the Executive Committee from the 2025 Annual General Meeting t” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group5,493,2290 00For
T. Rowe Price1,732,5302,924 00For
State Street0233,974 00Against
Vanguard0221,212 00Against
Fidelity0151,641 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
RMB INVESTORS TRUST039,367 00Against
Direxion Shares ETF Trust028,769 00Against
Northern Trust022,183 00Against
MassMutual19,6360 00For
American Century016,402 00Against
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds012,700 00Against
Guggenheim07,735 00Against
ProShares04,884 00Against
Empower2,2430 00For
Dimensional01,024 00Against
Franklin Templeton0737 00Against
SA FUNDS INVESTMENT TRUST0708 00Against
Prudential/PGIM0618 00Against
WisdomTree0573 00Against
Goldman Sachs0263 00Against
Invesco0207 00Against

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

Non-Binding Advisory Vote on the Compensation Paid to the Company’s Named Executive Officers Under U.S. Securities Law…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 24 wordings of this item as funds reported it.

71% Approved · of votes cast

FOR 71%AGAINST
FOR: 29,063,586AGAINST: 11,729,542

Prior year: 74.9% for (May 30, 2024 meeting) ▼ 3.6 pts

Details: description as filed, official tally, votes by 435 asset managers

Description as filed by funds: Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securities law requirements.

CRISPR THERAPEUTICS AG’s own tally for this item (“7. Non-Binding Advisory Vote on the Compensation Paid to the Company’s Named Executive Officers Under U.S. Securities Law Requirements”): 29,063,586 for, 11,729,542 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 7 – Non-Binding Advisory Vote on the Compensation Paid to the Company’s Named Executive Officers Under U.S. Securities Law Requirements The compensation paid to the named executive officers was approved on a non-binding basis.”
Support: 71% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 49 asset managers voting on “Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securi” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group5,493,2290 00For
T. Rowe Price01,735,454 00Against
Jackson National0283,472 00Against
State Street0233,974 00Against
Vanguard0221,223 00Against
Fidelity0151,641 00Against
Charles Schwab088,948 00Against
Natixis083,372 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST039,367 00Against
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust028,769 00Against
Capitol Series Trust022,300 00Against
Global X022,293 00Against
Northern Trust022,183 00Against
MassMutual019,636 00Against
ADVISORS SERIES TRUST17,3100 00For
American Century016,402 00Against
Nationwide016,111 00Against
Northwestern Mutual014,200 00Against
Blackstone Alternative Investment Funds012,700 00Against

Fund voting reports, all 49 managers: 15,155,999 for, 3,167,242 against, 0 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 396 asset managers voting on “Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securi” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group6,168,0270 00For
T. Rowe Price02,675,291 00Against
Nikko Asset Management Co., Ltd.02,539,889 00Against
NEA Management Company, LLC1,590,0020 00For
EcoR1 Capital, LLC1,389,2760 00For
SR ONE CAPITAL MANAGEMENT, LP1,048,9510 00For
Loomis Sayles0666,619 00Against
Versant Venture Management, LLC500,0280 00For
State Street0329,669 00Against
Contrarius Group Holdings Ltd317,4480 00For
CAPITAL ADVISORS INC/OK270,1730 00For
ARK Investment Management LLC222,8680 00For
STATE OF MICHIGAN RETIREMENT SYSTEM0222,852 00Against
JPMorgan0220,641 00Against
Vestmark Advisory Solutions, Inc.0219,430 00Against
MARSHALL WACE, LLP0215,172 00Against
BlackRock5,508207,437 00Against
Fidelity0207,459 00Against
Two Sigma0160,369 00Against
Northern Trust0128,180 00Against
Charles Schwab088,948 00Against
Lazard087,507 00Against
RBC Capital Markets, LLC087,412 00Against
Reynders McVeigh Capital Management, LLC085,443 00Against
ROCKEFELLER FINANCIAL LLC82,6410 00For

Institutional-manager reports, all 396 managers: 11,905,817 for, 9,058,511 against, 2,830 abstained, 3,149 not voted, 9,535 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Non-binding advisory vote on the 2024 Compensation Report.

Combines 3 wordings of this item as funds reported it.

94% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: votes by 70 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 21 asset managers voting on “Non-binding advisory vote on the 2024 Compensation Report.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Jackson National0283,472 00Against
Charles Schwab088,948 00Against
Natixis083,372 00Against
AMERICAN BEACON FUNDS53,3570 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Capitol Series Trust022,300 00Against
Global X022,293 00Against
ADVISORS SERIES TRUST17,3100 00For
BlackRock010,022 00Against
Loomis Sayles06,635 00Against
EA Series Trust2,8400 00For
Allianz02,134 00Against
JPMorgan01,394 00Against
CITY NATIONAL ROCHDALE FUNDS0410 00Against
Amplify ETF Trust0224 00Against
Jacob Funds Inc.1500 00For
John Hancock0126 00Against
Listed Funds Trust980 00For
Vanguard010 00Against

Fund voting reports, all 21 managers: 9,662,770 for, 521,340 against, 0 abstained.

Institutional-manager reports: 49 asset managers voting on “Non-binding advisory vote on the 2024 Compensation Report.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
SR ONE CAPITAL MANAGEMENT, LP1,048,9510 00For
Versant Venture Management, LLC500,0280 00For
BlackRock5,508184,179 00Against
WESTWOOD HOLDINGS GROUP INC38,8430 00For
Sand Hill Global Advisors, LLC08,655 00Against
BRANDYWINE OAK PRIVATE WEALTH LLC2,5000 00For
MERCER GLOBAL ADVISORS INC /ADV1,8240 00For
Abundance Wealth Counselors01,742 00Against
Evercore Wealth Management, LLC01,400 00Against
First Trust687564 00Mixed
Bath Savings Trust Co1,2250 00For
Atlantic Union Bankshares Corp01,200 00Against
L. Roy Papp & Associates, LLP1,0000 00For
EVERGREEN CAPITAL MANAGEMENT LLC7880 00For
FINANCIAL COUNSELORS INC0652 00Against
Argent Advisors, Inc.0500 00Against
Crestwood Advisors Group, LLC0432 00Against
NAPLES GLOBAL ADVISORS, LLC3950 00For
Sonora Investment Management Group, LLC3300 00For
STEPHENS INC /AR/3210 00For
EXENCIAL WEALTH ADVISORS, LLC3180 00For
Argent Trust Co0316 00Against
Chicago Partners Investment Group LLC3000 00For
Haverford Trust Co0254 00Against
Pine Haven Investment Counsel, Inc2000 00For

Institutional-manager reports, all 49 managers: 1,604,176 for, 200,934 against. Showing the 25 largest; every one is in the interactive database (link above).

Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July 1, 2025…

Combines 5 wordings of this item as funds reported it.

98% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 36 asset managers

Description as filed by funds: Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July 1, 2025 to June 30, 2026.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 21 asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Jackson National86,878196,594 00Mixed
Charles Schwab88,9480 00For
Natixis083,372 00Against
AMERICAN BEACON FUNDS53,3570 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Capitol Series Trust22,3000 00For
Global X22,2930 00For
ADVISORS SERIES TRUST17,3100 00For
BlackRock010,022 00Against
Loomis Sayles06,635 00Against
EA Series Trust2,8400 00For
Allianz02,134 00Against
JPMorgan1,3940 00For
CITY NATIONAL ROCHDALE FUNDS4100 00For
Amplify ETF Trust0224 00Against
Jacob Funds Inc.1500 00For
John Hancock1260 00For
Listed Funds Trust980 00For
Vanguard110 00For

Fund voting reports, all 21 managers: 9,885,130 for, 298,981 against, 0 abstained.

Institutional-manager reports: 15 asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
NEA Management Company, LLC1,590,0020 00For
SR ONE CAPITAL MANAGEMENT, LP1,048,9510 00For
Versant Venture Management, LLC500,0280 00For
Janney Montgomery Scott LLC10,8190 00For
BRANDYWINE OAK PRIVATE WEALTH LLC2,5000 00For
L. Roy Papp & Associates, LLP1,0000 00For
EXENCIAL WEALTH ADVISORS, LLC3180 00For
Rodgers Brothers Inc.0300 00Against
Sterling Investment Counsel, LLC0200 00Against
Summit Trail Advisors, LLC1930 00For
NORTHCAPE WEALTH MANAGEMENT, LLC1640 00For
BIRCHBROOK, INC.1000 00For
Petros Family Wealth, LLC850 00For
Hendershot Investments Inc.010 00Against
BRADY FAMILY WEALTH, LLC10 00For

Institutional-manager reports, all 15 managers: 3,154,161 for, 510 against.

F Non-binding advisory vote on the 2024 Compensation Report.

No official matchCOMPENSATION

68% of fund votes cast · no official result

FORAGAINST
Details: description as filed, votes by 30 asset managers

Description as filed by funds: f Non-binding advisory vote on the 2024 Compensation Report.

The 30 asset managers below reported 5,493,924 for, 2,643,401 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 5,493,924AGAINST: 2,643,401
Largest asset managers voting on “f Non-binding advisory vote on the 2024 Compensation Report.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group5,493,2290 00For
T. Rowe Price01,735,454 00Against
State Street0233,974 00Against
Vanguard0221,212 00Against
Fidelity0151,641 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
RMB INVESTORS TRUST039,367 00Against
Direxion Shares ETF Trust028,769 00Against
Northern Trust022,183 00Against
MassMutual019,636 00Against
American Century016,402 00Against
Nationwide016,111 00Against
Northwestern Mutual014,200 00Against
Blackstone Alternative Investment Funds012,700 00Against
Guggenheim07,735 00Against
ProShares04,884 00Against
Empower02,243 00Against
Dimensional01,024 00Against
Franklin Templeton0737 00Against
SA FUNDS INVESTMENT TRUST0708 00Against
Vident Advisory, LLC6950 00For
Prudential/PGIM0618 00Against
WisdomTree0573 00Against
Goldman Sachs0263 00Against

Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).

Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on…

No official matchCOMPENSATION

Combines 2 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 30 asset managers

Description as filed by funds: Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2024 Compensation Report: 6.a Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders.

The 30 asset managers below reported 8,136,630 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 8,136,630
Largest asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
State Street233,9740 00For
Vanguard221,2120 00For
Fidelity151,6410 00For
Equitable56,9460 00For
Lincoln Financial55,5450 00For
RMB INVESTORS TRUST39,3670 00For
Direxion Shares ETF Trust28,7690 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
American Century16,4020 00For
Nationwide16,1110 00For
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For
Guggenheim7,7350 00For
ProShares4,8840 00For
Empower2,2430 00For
Dimensional1,0240 00For
Franklin Templeton7370 00For
SA FUNDS INVESTMENT TRUST7080 00For
Prudential/PGIM6180 00For
WisdomTree5730 00For
Goldman Sachs2630 00For
Invesco2070 00For

Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).

C Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2025…

No official matchCOMPENSATION

92% of fund votes cast · no official result

FOR
Details: description as filed, votes by 29 asset managers

Description as filed by funds: c Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2025 to June 30, 2026.

The 29 asset managers below reported 7,483,212 for, 653,418 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,483,212AGAINST: 653,418
Largest asset managers voting on “c Binding vote on maximum non-performance-related compensation for members of the Executive Committee from Jul” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group5,493,2290 00For
T. Rowe Price1,732,5302,924 00For
State Street0233,974 00Against
Vanguard221,2120 00For
Fidelity0151,641 00Against
Equitable056,946 00Against
Lincoln Financial055,545 00Against
RMB INVESTORS TRUST039,367 00Against
Direxion Shares ETF Trust028,769 00Against
Northern Trust022,183 00Against
MassMutual19,6360 00For
American Century016,402 00Against
Nationwide016,111 00Against
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds012,700 00Against
Guggenheim07,735 00Against
ProShares04,884 00Against
Empower2,2430 00For
Dimensional01,024 00Against
Franklin Templeton0737 00Against
SA FUNDS INVESTMENT TRUST0708 00Against
Prudential/PGIM0618 00Against
WisdomTree0573 00Against
Goldman Sachs0263 00Against
Invesco0207 00Against

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

Re-election of the Auditors

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 60,674,825AGAINST: 340,077
Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: Re-election of the auditors.

CRISPR THERAPEUTICS AG’s own tally for this item (“10. Re-election of the Auditors”): 60,674,825 for, 340,077 against, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 18,301,717 for, 224 against, 22,320 abstained.

FOR
FOR: 18,301,717AGAINST: 224ABSTAIN: 22,320
Largest asset managers voting on “Re-election of the auditors.” at CRISPR THERAPEUTICS AG, 2024-2025
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust9,517,5850 00For
Capital Group5,493,2290 00For
T. Rowe Price1,735,4540 00For
Jackson National283,4720 00For
State Street233,9740 00For
Vanguard221,2230 00For
Fidelity151,6410 00For
Charles Schwab88,9480 00For
Natixis83,3720 00For
Equitable56,9460 00For
Lincoln Financial55,5450 00For
AMERICAN BEACON FUNDS53,3570 00For
RMB INVESTORS TRUST39,3670 00For
ARK Venture Fund38,1620 00For
Investment Managers Series Trust II33,2680 00For
Direxion Shares ETF Trust28,7690 00For
Capitol Series Trust00 22,3000Abstain
Global X22,2930 00For
Northern Trust22,1830 00For
MassMutual19,6360 00For
ADVISORS SERIES TRUST17,3100 00For
American Century16,4020 00For
Nationwide16,1110 00For
Northwestern Mutual14,2000 00For
Blackstone Alternative Investment Funds12,7000 00For

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Showing the 40 reported items with the widest manager coverage, of 43 in total. Every item is in the interactive database (link above).

Not shown here: this season’s fund filings also report 1 item from the meeting of May 30, 2024, which belongs to the 2023-2024 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest CRISPR THERAPEUTICS AG shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 86,360,924 shares outstanding at the time of that meeting.

Fund voting reports: top CRISPR THERAPEUTICS AG shareholders by shares voted on “Non-binding advisory vote on the compensation paid to the Company's named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1ARK ETF Trust 11.02%
2Capital Group 6.36%
3T. Rowe Price 2.01%
4Jackson National 0.33%
5State Street 0.27%
6Vanguard 0.26%
7Fidelity 0.18%
8Charles Schwab 0.10%
9Natixis 0.10%
10Equitable 0.07%
Institutional-manager reports: top CRISPR THERAPEUTICS AG shareholders by shares voted on “Non-binding advisory vote on the compensation paid to the Company's named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1Capital Group 7.14%
2T. Rowe Price 3.10%
3Nikko Asset Management Co., Ltd. 2.94%
4NEA Management Company, LLC 1.84%
5EcoR1 Capital, LLC 1.61%
6SR ONE CAPITAL MANAGEMENT, LP 1.21%
7Loomis Sayles 0.77%
8Versant Venture Management, LLC 0.58%
9State Street 0.38%
10Contrarius Group Holdings Ltd 0.37%

Reported CRISPR THERAPEUTICS AG holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

CRISPR THERAPEUTICS AG holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
ARK Investment Management LLC11,313,623 13.10%Schedule 13G, filed April 30, 2026
Capital Research and Management Company8,223,994 9.52%Proxy statement (DEF 14A), proxy filed April 16, 2025
ORBIS INVESTMENT MANAGEMENT LTD6,090,194 7.05%Schedule 13G, filed May 15, 2026
Capital World Investors4,929,428 5.71%Schedule 13G, filed May 14, 2026
BlackRock2,613,539 3.03%Form 13F, quarter ended March 31, 2025
State Street2,411,262 2.79%Form 13F, quarter ended March 31, 2025
FMR (Fidelity)1,940,545 2.25%Form 13F, quarter ended March 31, 2025
Vanguard Group1,769,709 2.05%Form 13F, quarter ended March 31, 2025
Samarth Kulkarni, Ph.D.1,466,246 1.70%Proxy statement (DEF 14A), proxy filed April 16, 2025
Morgan Stanley1,299,982 1.51%Form 13F, quarter ended March 31, 2025

Percentages above are of 86,360,924 shares outstanding, as reported by CRISPR THERAPEUTICS AG on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At CRISPR THERAPEUTICS AG's shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 440 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 4,250 separate fund positions. Their filings are grouped here into 43 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Non-binding advisory vote on the compensation paid to the Company's named executive officers… — CRISPR THERAPEUTICS AG's filing reports the proposal as approved, with 71% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CRISPR THERAPEUTICS AG's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CRISPR THERAPEUTICS AG’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

CRISPR THERAPEUTICS AG proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “CRISPR THERAPEUTICS (CRSP) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/crispr-therapeutics-ag/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.